April 2026 in “International Journal of Dermatology” This review explores the potential links between PRP treatments for hair loss and scalp skin cancer risk, finding current evidence supports PRP's safety but emphasizes the need for further studies and routine monitoring.
July 2024 in “Journal of Investigative Dermatology” Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.
This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.
25 citations
,
May 2018 in “Clinical & Translational Oncology” This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.
6 citations
,
September 2013 in “Journal of Evolution of Medical and Dental Sciences” This study observed a wide range of mucocutaneous disorders among HIV-infected individuals in India, with a significant association between low CD4 cell counts and the presence of infectious and inflammatory skin conditions.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.
7 citations
,
October 2019 in “Annals of palliative medicine” This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.
April 2026 in “IntechOpen eBooks” This study reviews the complexities of burn-related skin complications, highlighting postburn pruritus, dyspigmentation, and the risk of malignant ulcers, while offering a framework for evidence-based management through various treatment approaches.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
62 citations
,
April 2009 in “British Journal of Dermatology” This review discusses the potential markers for identifying and studying stem cells in the epidermis and hair follicles, highlighting their role in understanding skin disease pathogenesis and expanding therapeutic options, but reports no new findings.
60 citations
,
May 2015 in “Archives of dermatological research” This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.
60 citations
,
September 2013 in “Alimentary Pharmacology & Therapeutics” This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.
46 citations
,
July 2022 in “Frontiers in Oncology” This review discusses recent advancements in cold atmospheric plasma therapies for dermatology, covering optimization, treatment of skin diseases, safety, and does not report new clinical outcomes; it calls for continued research in the field.
8 citations
,
January 2019 in “JAAD Case Reports” This article describes erosive pustular dermatosis of the scalp, emphasizing its chronic nature, potential complications, and the lack of specific diagnostic findings, but reports no new clinical results.
2 citations
,
November 2025 in “Pharmaceutics” This review explores the potential of cell-mediated drug delivery systems in dermatology, highlighting their ability to target inflamed or diseased skin while discussing applications in diseases like atopic dermatitis and melanoma, along with challenges such as immunogenicity and manufacturing.
2 citations
,
September 2010 in “Journal of the Dermatology Nurses’ Association” This article provides a detailed analysis of immunosuppressive medications in transplant patients and discusses the increased risk of skin cancer, but it reports no new experimental results.
January 2025 in “International Journal of Dermatology” This case report describes a patient with eruptive tumor of follicular infundibulum, emphasizing the need for dermatologists to include it in the differential diagnosis of acquired facial hypopigmentation.
May 2023 in “Dermatology Online Journal” No increased skin cancer risk was found in alopecia patients treated with photobiomodulation.
66 citations
,
December 2013 in “Nature Cell Biology” This study found that quiescence in hair follicle stem cells acts as a tumor suppression mechanism for cutaneous squamous cell carcinoma, with Pten activity necessary to maintain this state.
39 citations
,
March 2009 in “Dermatology Online Journal” This review observes that trichomegaly, a newly described side effect of EGFR inhibitors causing excessive eyelash and scalp hair growth, persists in some patients whose tumors respond positively to the therapy.
November 2013 in “International Journal of Dermatology” New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.
105 citations
,
December 2003 in “Veterinary Dermatology” This review discusses the association between cutaneous paraneoplastic syndromes and internal malignancies, noting that recognition of these skin disorders may help detect underlying cancers, but reports no new research findings.
1 citations
,
December 2014 in “Zenodo (CERN European Organization for Nuclear Research)” This protocol details a method for inducing skin cancer in mice through chemical carcinogenesis, which studies cutaneous malignancies but does not report new findings.
April 2025 in “International Journal of Dermatology” This review by St. Denis et al. highlights that prostaglandin E2 is overexpressed in several skin cancers and suggests targeting its pathway could offer potential treatments for these malignancies.
October 2020 in “Our Dermatology Online” This report presents two cases where dermatologists identified internal malignancies—small cell lung cancer and stage IIB cervical cancer—through paraneoplastic skin manifestations.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
April 2024 in “Nepal journal of dermatology, venereology & leprology” This review highlights that vitamin D is increasingly recognized for its roles in skin health, including treatment of psoriasis, potential applications in conditions like atopic dermatitis, and possible prevention of skin malignancies, as observed in various studies linking low levels to autoimmune skin diseases.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
29 citations
,
September 2017 in “Oncology and therapy” This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.